Article

April 4, 2013

Robert W. Dubois, MD, PhD, Describes the Initial Expectations of Accountable Care Organizations

Robert W. Dubois, MD, PhD, the chief science officer of the National Pharmaceutical Council discusses the initial expectations of implementing accountable care organizations (ACOs) and how those expectations have evolved over time.

This video was taken at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo in San Diego, CA, on April 4, 2013.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Joshua K. Sabari, MD | Image: NYU Langone

Published: July 1st 2025 | Updated: June 30th 2025

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Joshua K. Sabari, MD Interview by Mary Caffrey

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.

June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS

Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.

Doctor looking at lung imaging | Image credit: shidlovski – stock.adobe.com

June 26th 2025

Deep Learning Biomarkers Help Uncover ENV-101 Treatment Effects in IPF

Hayden E. Klein

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

December 31st 2024

AJMC® Editors Reflect on 2024 and Look Forward to a Milestone

Christina Mattina

The editors in chief of The American Journal of Managed Care® discuss the key managed care research and news from 2024 and look forward to the journal’s upcoming 30th anniversary.

3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com

June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

Richard J. Nowak, MD, MS | Image Credit: Yale School of Medicine

June 24th 2025

Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS

Maggie L. Shaw Richard J. Nowak, MD, MS

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.